Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
19.04 USD +2.26% Intraday chart for Sage Therapeutics, Inc. -3.25% -12.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating MT
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines MT
Transcript : Sage Therapeutics, Inc., Q4 2023 Earnings Call, Feb 14, 2024
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M MT
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Wedbush Adjusts Sage Therapeutics' Price Target to $24 From $22, Keeps Neutral Rating MT
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC CI
Oppenheimer Adjusts Sage Therapeutics Price Target to $23 From $20, Maintains Perform Rating MT
Transcript : Sage Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM
Sage Therapeutics, Inc. Announces Changes to Board of Directors CI
Stifel Cuts Price Target on Sage Therapeutics to $20 From $22, Maintains Hold Rating MT
Biogen, Sage Therapeutics Say Oral Pill Zurzuvae for Postpartum Depression Now Available by Prescription in US MT
Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE 50 mg (Two 25 mg Capsules Per Day) CIV CI
Deutsche Bank Initiates Coverage on Sage Therapeutics With Hold Rating, $21 Price Target MT
RBC Trims Price Target on Sage Therapeutics to $21 From $22, Keeps Sector Perform, Speculative Risk MT
Wedbush Lifts Sage Therapeutics' PT to $22 From $21, Says Zurzuvae Pricing In-Line With Expectations; Maintains Neutral Rating MT
Sage Therapeutics Q3 Loss Widens; Revenue Rises MT
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 RE
Transcript : Sage Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Sage Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart Sage Therapeutics, Inc.
More charts
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing brain health medicines. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous systems (CNS) receptor systems, GABA and NMDA. It targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The Company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
19.04 USD
Average target price
27.42 USD
Spread / Average Target
+44.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Sage Therapeutics, Inc. - Nasdaq
  4. News Sage Therapeutics, Inc.
  5. Sage Therapeutics : Truist Adjusts Sage Therapeutics' Price Target to $70 From $60, Reiterates Hold Rating